Onset of Type 1 Diabetes Mellitus During Pegylated-interferon Alfa and Ribavirin Therapy for Chronic Hepatitis C Virus Infection

Raghini Ranganathan; Krishnaveni Janarthanan; Senthilkumar Rajasekaran

doi:10.1016/S0973-6883(12)60089-9

Onset of Type 1 Diabetes Mellitus During Pegylated-interferon Alfa and Ribavirin Therapy for Chronic Hepatitis C Virus Infection

J Clin Exp Hepatol. 2012 Mar;2(1):86-7. doi: 10.1016/S0973-6883(12)60089-9. Epub 2012 Apr 12.

Authors

Raghini Ranganathan¹, Krishnaveni Janarthanan¹, Senthilkumar Rajasekaran¹

Affiliation

¹ Department of Gastroenterology, PSG Institute of Medical Sciences and Research, Coimbatore - 641004, Tamil Nadu, India.

Abstract

A 16-year-old female was treated with pegylated-interferon (PEG-IFN) alfa (a)-2b and ribavirin combination therapy for chronic hepatitis C virus (HCV) infection. She attained rapid virological response. She presented with diabetic ketoacidosis after 41 weeks of therapy. Anti-glutamic acid decarboxylase antibodies and islet cell antibodies were negative. Her fasting serum C-peptide level was <0.1 ng/mL, and the treatment course was completed. This case underlines the importance of periodic plasma glucose monitoring in patients during and after PEG-IFN and ribavirin therapy.

Keywords: BMI, body mass index; DM, diabetes mellitus; Diabetes mellitus; HCV, hepatitis C virus; HLA, human lymphocyte antigen; ICA, islet cell antibodies; MHC, major histocompatibility complex; PEG-IFN, pegylated-interferon; SC, subcutaneously; SGPT, serum glutamic-pyruvic transaminase; hepatitis C virus; interferon.